Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ND0612 in Parkinson's Disease Patients With Motor Fluctuations
NCT01883505Phase 2Completed
- Sponsor
- NeuroDerm Ltd.
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ND0612 in Parkinson's disease (PD) (4 arms), sponsored by NeuroDerm Ltd. Primary endpoints: Safety and Tolerability at 7 weeks and Pharmacokinetics at 21 days. Started Jan 2014; status: completed.
02
Drugs
ND0612
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01883505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01883505.